Can urine osteopontin levels, which may be correlated with nutrition intake and body composition, be used as a new biomarker in the diagnosis of nephrolithiasis?

İçer, Mehmet Arif; Karadağ, Makbule Gezmen; Sözen, Sinan

doi:10.1016/j.clinbiochem.2018.08.001

Cited by 19 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several researchers have reported that urine OPN level-normalized creatinine was lower in stone forming urolithiasis patients than in HVs and also generated aberrant OPN forms (<40 kDa) [12,14,16,17]. OPN has important functions in cardiovascular diseases, cancer, diabetes and kidney stone diseases and in the process of inflammation, biomineralization, cell viability, and wound healing [18].…”

Section: Discussionmentioning

confidence: 99%

The Impact of Glycosylation of Osteopontin on Urinary Stone Formation

Anan

Yoneyama

Noro

et al. 2019

IJMS

View full text Add to dashboard Cite

Osteopontin (OPN) is a matrix glycoprotein of urinary calculi. This study aims to identify the role of aberrant glycosylation of OPN in urolithiasis. We retrospectively measured urinary glycosylated OPN normalized by urinary full-length-OPN levels in 110 urolithiasis patients and 157 healthy volunteers and 21 patients were prospectively longitudinal follow-up during stone treatment. The urinary full-length-OPN levels were measured using enzyme-linked immunosorbent assay and glycosylated OPN was measured using a lectin array and lectin blotting. The assays were evaluated using the area under the receiver operating characteristics curve to discriminate stone forming urolithiasis patients. In the retrospective cohort, urinary Gal3C-S lectin reactive-(Gal3C-S-) OPN/full-length-OPN, was significantly higher in the stone forming urolithiasis patients than in the healthy volunteers (p < 0.0001), with good discrimination (AUC, 0.953), 90% sensitivity, and 92% specificity. The Lycopersicon esculentum lectin analysis of urinary full-length-OPN showed that urinary full-length-OPN in stone forming urolithiasis patients had a polyLacNAc structure that was not observed in healthy volunteers. In the prospective longitudinal follow-up study, 92.8% of the stone-free urolithiasis group had Gal3C-S-OPN/full-length-OPN levels below the cutoff value after ureteroscopic lithotripsy (URS), whereas 71.4% of the residual-stone urolithiasis group did not show decreased levels after URS. Therefore, Gal3C-S-OPN/full-length-OPN levels could be used as a urolithiasis biomarker.

show abstract

Section: Discussionmentioning

confidence: 99%

The Impact of Glycosylation of Osteopontin on Urinary Stone Formation

Anan

Yoneyama

Noro

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…This result suggested that the Huashi Pill triggered clearance of stones might be triggered by reducing the OPN protein levels in kidney tissue. We must emphasize that the levels of OPN in the kidney tissue were taken into account in our study, because that the OPN level in kidney tissue and urinary OPN level have different effects on kidney stone formation [31]. For the urinary OPN, the lower OPN levels might be positively correlated with the increased risk of renal stone [31].…”

Section: Discussionmentioning

confidence: 99%

Inhibitive Effects of Huashi Pill on Formation of Renal Stones by Modulating Urine Biochemical Indexes and Osteopontin in Renal Stone Rat Models

YANG

Guo

et al. 2019

Med Sci Monit

View full text Add to dashboard Cite

BackgroundRenal stones are the accumulated or deposited crystals that form and appear in supersaturated urine. This study aimed to the investigate the therapeutic effects of Huashi Pill on clearance of renal stones.Material/MethodsSprague Dawley rats were divided into normal control, positive control, low-dosage Huashi Pill, medium-dosage Huashi Pill, and high-dosage Huashi Pill groups. A renal rat model was established by using ethylene glycol, ammonium chloride, and calcium gluconate. The urinary pH, urine protein, and uric acid levels, as well as the calcium, magnesium, and phosphorus levels were examined. The blood urea nitrogen (BUN) and creatinine (Cr) levels were also evaluated. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin (TBIL) levels were evaluated. Crystal formation and calcium deposits were examined using hematoxylin and eosin (H and E) staining and von Kossa staining, respectively. Osteopontin (OPN) expression was evaluated with quantitative real-time polymerase chain reaction assay and immunohistochemical assay.ResultsA renal stone rat model was successfully established. Huashi Pill significantly improved water and food intake and enhanced pH value of urine (P<0.05). Huashi Pill significantly improved the liver functions by decreasing ALT and TBIL levels (P<0.05). Huashi Pill regulated the amounts of microelements. Huashi Pill significantly decreased the urine protein, uric acid, and Cr levels (P<0.05). Huashi Pill inhibited formation of stone crystals and reduced the insoluble calcium deposition. Huashi Pill significantly downregulated expression of OPN in the kidney tissues of renal rat models (P<0.05).ConclusionsHuashi Pill inhibited stone formation by regulating urine biochemical indexes and reducing OPN expression in kidney tissue in a renal stone rat model.

show abstract

“…OPN’s role in the normal human kidney is not fully explained; however, it is believed that this protein is involved in tubulogenesis (Rogers et al 1997 ). In addition, numerous studies have been conducted to evaluate OPN’s role in renal stone formation, but the obtained results are contradictory and inconclusive (Icer et al 2018 ; Tsuji et al 2007 ). It has been demonstrated that OPN expression is increased in numerous kidney diseases, including cancer, immunoglobulin A nephropathy, diabetic nephropathy, minimal change disease, focal and segmental glomerulosclerosis, membranous glomerulonephritis, and lupus nephritis (reviewed in Kaleta 2019a ).…”

Section: Opn In Kidney Transplantationmentioning

confidence: 99%

Osteopontin and Transplantation: Where Are We Now?

Kaleta

2021

Arch. Immunol. Ther. Exp.

View full text Add to dashboard Cite

Organ transplantation represents the optimal therapeutic tool for patients with end-stage organ failure. Hematopoietic stem cell transplantation (HSCT) is likewise an effective therapy for a wide range of malignant and non-malignant diseases. Better understanding of transplantation immunology and the use of multi-modal immunosuppression protocols, can decrease the risk of graft failure and graft-versus-host disease (GVHD) after HSCT. Nevertheless, a major challenge of modern transplantology still seems to be finding non-invasive biomarkers for recipients selection, monitoring of allograft function, and diagnosis of rejection. Since proinflammatory cytokine osteopontin (OPN) is closely involved in regulating both adaptive and innate immune responses, as well as the pathogenesis of inflammatory and autoimmune diseases, it is likely to play an important role in organ and HSC transplantation. This review is to summarize recent advances in our knowledge about OPN function in the kidney, heart, liver, lung, and HSC transplantation. Most studies found that elevated OPN is associated with poorer graft function in kidney, heart, liver and lung recipients. Moreover, some reports suggested that this protein can play role in GVHD pathogenesis. However, due to relatively small number of similar studies, as well as some inconclusive results, future investigation in this field is needed to verify if OPN can serve as a biomarker of organ and HSC transplantation. The knowledge about such markers will promote our understanding of the mechanisms underlying graft dysfunction and posttransplant mortality. In addition, such knowledge may be helpful in the development of new treatment strategies and identification of recipients with increased risk of allograft failure.

show abstract

Can urine osteopontin levels, which may be correlated with nutrition intake and body composition, be used as a new biomarker in the diagnosis of nephrolithiasis?

Cited by 19 publications

References 31 publications

The Impact of Glycosylation of Osteopontin on Urinary Stone Formation

The Impact of Glycosylation of Osteopontin on Urinary Stone Formation

Inhibitive Effects of Huashi Pill on Formation of Renal Stones by Modulating Urine Biochemical Indexes and Osteopontin in Renal Stone Rat Models

Osteopontin and Transplantation: Where Are We Now?

Contact Info

Product

Resources

About